The approval of Boehringer Ingelheim's anticancer drug afatinib highlights the growing enthusiasm for once-shunned irreversible kinase inhibitors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Journal of Hematology & Oncology Open Access 02 March 2022
-
Divergent synthesis and identification of the cellular targets of deoxyelephantopins
Nature Communications Open Access 19 August 2016
-
Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
Scientific Reports Open Access 20 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Sanderson, K. Irreversible kinase inhibitors gain traction. Nat Rev Drug Discov 12, 649–651 (2013). https://doi.org/10.1038/nrd4103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4103
This article is cited by
-
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Journal of Hematology & Oncology (2022)
-
The impact of structural biology in medicine illustrated with four case studies
Journal of Molecular Medicine (2018)
-
Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
Scientific Reports (2016)
-
Divergent synthesis and identification of the cellular targets of deoxyelephantopins
Nature Communications (2016)
-
Protein tyrosine phosphatases as potential therapeutic targets
Acta Pharmacologica Sinica (2014)